AgeBiotics™ as Precision Co-Therapeutics in IBD: AI-Optimized Modulation of Gut Microbial Metabolism

Crohn’s disease (CD) is a chronic inflammatory condition marked by gut microbial dysbiosis that is often unresolved by current therapies. This study evaluated five AI-optimized formulations, synergistic combinations of small molecules, minerals, and peptides optimized by artificial intelligence (AI) to increase their potential as precision co-therapeutics. Using a validated ex vivo intestinal fermentation assay (SIFR®) with fecal samples from ten CD patients, we assessed the formulations' impact on microbial metabolism. All formulations significantly increased the production of beneficial short-chain fatty acids (SCFAs) indicating efficient metabolic processing. Each formulation displayed a unique metabolic fingerprint; for instance, AB1 and AB3 maximized butyrate and propionate production, while AB4 uniquely suppressed branched-chain fatty acids (BCFAs), signaling a shift towards other, potentially beneficial protein-derived metabolites. The notable inter-donor variability in response highlights the potential for personalized applications. These findings demonstrate that AI-optimized AgeBiotics™ can precisely modulate gut microbial function, offering a promising and tolerable approach to support gut health in CD and providing a strong rationale for clinical trials.